Profund Advisors’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $316K | Buy |
38,069
+4,963
| +15% | +$51.4K | 0.01% | 720 |
|
|
2025
Q4 | $409K | Buy |
33,106
+12,681
| +62% | +$136K | 0.01% | 668 |
|
|
2025
Q3 | $180K | Buy |
20,425
+3,937
| +24% | +$30.6K | 0.01% | 1001 |
|
|
2025
Q2 | $105K | Sell |
16,488
-5,504
| -25% | -$31.5K | ﹤0.01% | 961 |
|
|
2025
Q1 | $107K | Sell |
21,992
-4,569
| -17% | -$37.8K | ﹤0.01% | 948 |
|
|
2024
Q4 | $254K | Sell |
26,561
-682
| -3% | -$6.26K | 0.01% | 863 |
|
|
2024
Q3 | $227K | Buy |
+27,243
| New | +$248K | 0.01% | 977 |
|
|
2023
Q3 | – | Sell |
-106,196
| Closed | -$781K | – | 1010 |
|
|
2023
Q2 | $781K | Buy |
106,196
+33,410
| +46% | +$310K | 0.04% | 385 |
|
|
2023
Q1 | $754K | Buy |
+72,786
| New | +$880K | 0.05% | 376 |
|
|
2022
Q3 | – | Sell |
-9,635
| Closed | -$299K | – | 946 |
|
|
2022
Q2 | $299K | Sell |
9,635
-3,002
| -24% | -$102K | 0.02% | 637 |
|
|
2022
Q1 | $519K | Buy |
12,637
+667
| +6% | +$29.4K | 0.02% | 549 |
|
|
2021
Q4 | $520K | Buy |
11,970
+482
| +4% | +$21.8K | 0.02% | 585 |
|
|
2021
Q3 | $575K | Sell |
11,488
-134
| -1% | -$8.12K | 0.02% | 560 |
|
|
2021
Q2 | $732K | Sell |
11,622
-178
| -2% | -$11.4K | 0.02% | 472 |
|
|
2021
Q1 | $1.1M | Sell |
11,800
-1,740
| -13% | -$178K | 0.04% | 288 |
|
|
2020
Q4 | $1.21M | Buy |
13,540
+1,738
| +15% | +$160K | 0.05% | 273 |
|
|
2020
Q3 | $1.22M | Buy |
11,802
+8,079
| +217% | +$871K | 0.06% | 245 |
|
|
2020
Q2 | $294K | Buy |
+3,723
| New | +$277K | 0.02% | 612 |
|
|
2020
Q1 | – | Sell |
-4,612
| Closed | -$249K | – | 889 |
|
|
2019
Q4 | $249K | Sell |
4,612
-770
| -14% | -$41.8K | 0.01% | 1046 |
|
|
2019
Q3 | $281K | Buy |
5,382
+1,232
| +30% | +$57.4K | 0.01% | 958 |
|
|
2019
Q2 | $200K | Sell |
4,150
-237
| -5% | -$11.4K | 0.01% | 1144 |
|
|
2019
Q1 | $222K | Sell |
4,387
-1,002
| -19% | -$59.1K | 0.01% | 1082 |
|
|
2018
Q4 | $319K | Sell |
5,389
-3,058
| -36% | -$197K | 0.02% | 716 |
|
|
2018
Q3 | $556K | Buy |
8,447
+192
| +2% | +$11.2K | 0.02% | 721 |
|
|
2018
Q2 | $417K | Buy |
8,255
+820
| +11% | +$42.7K | 0.02% | 917 |
|
|
2018
Q1 | $391K | Buy |
7,435
+2,071
| +39% | +$103K | 0.02% | 949 |
|
|
2017
Q4 | $249K | Sell |
5,364
-114
| -2% | -$4.8K | 0.01% | 1244 |
|
|
2017
Q3 | $222K | Buy |
+5,478
| New | +$198K | 0.01% | 1287 |
|
|
2017
Q1 | – | Sell |
-8,650
| Closed | -$284K | – | 1487 |
|
|
2016
Q4 | $284K | Buy |
+8,650
| New | +$259K | 0.01% | 1261 |
|
|
2016
Q1 | – | Sell |
-5,548
| Closed | -$222K | – | 1460 |
|
|
2015
Q4 | $222K | Buy |
+5,548
| New | +$193K | 0.01% | 1140 |
|
|
2015
Q3 | – | Sell |
-6,480
| Closed | -$214K | – | 1253 |
|
|
2015
Q2 | $214K | Sell |
6,480
-1,725
| -21% | -$53.5K | 0.01% | 1328 |
|
|
2015
Q1 | $236K | Buy |
+8,205
| New | +$235K | 0.01% | 1354 |
|
|
2014
Q1 | – | Sell |
-14,933
| Closed | -$343K | – | 1644 |
|
|
2013
Q4 | $343K | Sell |
14,933
-3,762
| -20% | -$78.4K | 0.02% | 1299 |
|
|
2013
Q3 | $356K | Buy |
+18,695
| New | +$334K | 0.02% | 1189 |
|
Other funds holding EBS
VCM
PCM
VPM
Profund Advisors's EBS Position: Q1 2026 in Review
Profund Advisors increased its Emergent Biosolutions (EBS) stake by 15% in Q1 2026, buying an estimated $51.4K and bringing the position to 38,069 shares worth $316K. The position accounts for 0.01% of the portfolio, ranked #720.
Profund Advisors first reported a position in EBS in Q3 2013 and has held it in 34 quarters since. The position peaked at $1.22M in Q3 2020. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.
- Profund Advisors held 38,069 shares of Emergent Biosolutions worth $316K as of Q1 2026.
- Profund Advisors bought 4,963 Emergent Biosolutions shares in Q1 2026, an estimated $51.4K.
- Emergent Biosolutions made up 0.01% of Profund Advisors's portfolio in Q1 2026, its #720 holding.
- Profund Advisors first reported a position in Emergent Biosolutions in Q3 2013 and has held it in 34 quarters since.
- Profund Advisors's Emergent Biosolutions position peaked at $1.22M in Q3 2020.
- 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.
Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.